

# ANGLO | LIFE SCIENCE NORDIC | CONFERENCE

DELIVERED DIGITALLY • 25TH - 26TH MAY 2021

## 2021 Programme

---

### Tuesday 25 May 2021

#### 09:00 The Right Hit Finding Approach for You

During this workshop, resident experts from WuXi AppTec discussed a range of different hit finding techniques which can be applied either individually or in parallel, depending on the target, to find tractable hit matter with the highest chance of being optimized into a drug.

---

#### 11:00 Standing Out from The Crowd Workshop

During this workshop hosted by marketing and media consultancy, Moxie Works, Maxine Fennell shared the 8 key components to build an effective marketing strategy. Whether you are looking to generate investment, boost brand awareness or raise your profile as opinion leader, this helped you understand your marketing more deeply and effectively.

Maxine shared experience and client case studies from years of experience of translating the diverse needs of businesses into clear and concise strategies with measurable outcomes.

---

#### 12:00 Fundraising Bootcamp & Branding and Messaging Workshop

European life science entrepreneurs are developing cutting-edge technologies that will require reliable funding sources beyond what is available in a given country or region. How to identify investors from across the globe that are a fit for a given technology and stage of development? How to get the attention of those investors? This interactive webinar covered these and other key topics and was hosted by Life Science Nation, organisers of the popular RESI series of investor events.

---

#### **14:00 Finding Funding Workshop**

This webinar hosted by SEHTA gave an overview of public sector funding opportunities: including how to write a successful grant application plus an overview of private sector funding opportunities: including how to produce an effective Investor Pitch slide deck. Speakers were Dr David Parry, former CEO, **SEHTA** and Nick Rodgers, Chair, **SEHTA**.

Each webinar delegate had the opportunity to apply for a one hour 1:1 Funding Review with the SEHTA team.

---

#### **15:00 The Next Frontier of Biotech - Roundtable Discussion**

During this roundtable discussion participants discussed the next frontier of biotech: turning the food industry from low-tech into high-tech. Why is now the time for biotech applications in food? What is still missing? How is the investor landscape changing?

**Moderated by:** Alex Hoffmann, **M Ventures**

#### **Speakers:**

- Maarten Bosch, **Mosa Meat**
  - Raffael Wohlgensinger, **Formo**
  - Mazen Rizk, **Mushlabs**
  - Sara Marquardt, **NxFoods**
  - Tom Simmons, **Supplant**
- 

## **Wednesday 26 May 2021**

#### **09:00 Welcome**

Mattias Johansson, **The Anglonordic Life Science Conference Founder & Director of Ezenze**

**Conference Chair:** Mary Clark, MD, **Optimum Strategic Communications**

---

#### **09:05 Keynote**

Kate Bingham, Managing Partner, **SV Health Investors**

---

#### **09:30 Panel Discussion: What Are the Hot Investment Areas?**

Europe's leading investors provided an overview of their outlook on the market, as well as current and future trends that are driving investment in the healthcare sector.

*Chaired by:* **Amber Tong, Endpoints**

**Panellists:**

- Hakan Goker, **M Ventures**
  - Deborah Harland, **SR One**
  - Nanna Lüneborg, **Novo Holdings**
  - Stephan Christgau, **EIR Ventures**
- 

**10:30 Keynote**

Dr Joern-Peter Halle, SVP, Global Head of Research, Healthcare, **Merck Healthcare**

---

**11:00 Company Presentations**

**Biotech Investment Company Presentations**

*Chaired by:* **Catherine Longworth, Web Editor, pharmaphorum**

- **11:00 - 11:05** **Welcome** from the session Chair
- **11:05 - 11:15** **Versameb**, focusing on discovering and developing innovative RNA-based drugs for modulation of protein expression and cellular targeting, including the ability to simultaneously influence several therapeutic targets, in a controlled manner, with a single molecular construct.
- **11:15 - 11:30** **Adare Pharma Solutions**, a global, technology-driven CDMO providing turnkey product development through commercial manufacturing expertise focused on oral dosage forms for the Pharmaceutical, Animal Health and OTC markets.
- **11:30 - 11:45** **VAXIMM**, a privately held Swiss/German biotech company that is developing oral T-cell immunotherapies.
- **11:45 - 12:00** **Macrophage Pharma**, focused on treating human disease by reprogramming macrophage function through transcriptional reprogramming and targeted drug-delivery leveraging proprietary Esterase Sensitive Motif™ (ESM™) platform.
- **12:00 - 12:15** **Gate2Brain**, a biotech company focused on the development of therapeutics that efficiently cross biological barriers such as the blood-brain barrier.
- **12:15 - 12:30** **SNIPR Biome**, a CRISPR and Microbiome company focused on the interplay between life-threatening infectious diseases treatment and prevention, the microbiome and Oncology.

**Technology Investment Company Presentations**

*Chaired by:* **Ian Bolland, Editor, Med-Tech Innovation News**

- **11:00 - 11:05** **Welcome** from the session Chair
- **11:05 - 11:15** **Santersus**, has developed a NucleoCapture selective apheresis device first in class fully functional product designed to capture and remove circulating cfDNA and Neutrophil Extracellular Traps (NETs) from patient blood to revolutionize how we control the human immune and inflammatory response.

- **11:15 - 11:30 Aortyx**, designs and develops medical devices to cure aortic diseases with the introduction of uniquely designed endovascular patches. Aortyx moves forward from conventional approaches, based on temporary repair, to definitive regeneration.
  - **11:30 - 11:45 Spirea**, a private antibody drug conjugate (ADC) biotech company spun out from the University of Cambridge, UK. The company will use its novel, wholly-owned, high drug-to-antibody ratio technology to improve ADC safety and efficacy and generate an exciting pipeline of differentiated therapeutics to treat a range of solid tumours.
  - **11:45 - 12:00 Ahead Therapeutics**, has developed an innovative solution based on the use of PS-liposomes containing auto-autoantigens. Through a biomimetic process, these liposomes can induce antigen specific immune tolerance, thereby interrupting the autoimmune reaction.
  - **12:00 - 12:15 IOMED**, a company located in Barcelona whose main objective is to accelerate clinical research, by helping hospitals to reuse their clinical information.
  - **12:15 - 12:30 SurePulse**, a company with a vision to revolutionise neonatal vital sign monitoring and give every baby the best start to life.
- 

### **12:30 The new Danish Life Science Strategy**

**Denmark recently launched a new Life Science Strategy to further develop this already strategically important industry. Presenters explained about the 38 initiatives to improve conditions for R&D and ensure better and more secure use of Denmark's unique health data, increase the number and quality of clinical trials in Denmark and better leverage digital health solutions and treatments.**

This interactive session was hosted by Invest in Denmark.

---

### **13:00 Panel Discussion: DDR Therapeutics**

**A panel of industry experts and investors discussed this exciting field of biology, clinically validated by the first-generation PARP inhibitors currently on the market. The panel discussed the strength of DNA Damage Response as an investment opportunity and how this hot area of biology will rapidly impact the clinic.**

*Chaired by: Lucie Ellis, In Vivo*

#### **Panellists:**

- Niall Martin, **Artios Pharma**
  - Mark O'Connor, **AstraZeneca**
  - Andree Blaukat, **Merck KGaA**
  - Simon Boulton, **Artios Pharma & Francis Crick Institute**
-

## 13:45 Company Presentations

### Biotech Investment Company Presentations

*Chaired by: Hollie Vile, Optimum Strategic Communications*

- **13:45 - 13:50** **Welcome** from the session Chair
- **13:50 - 14:00** **Indi Molecular**, developing a breakthrough, fully synthetic protein chemistry platform to transform targeted therapeutic and molecular imaging.
- **14:00 - 14:15** **Emenda Therapeutics**, a new UK-based RNA-splicing biotech founded on the world-leading insight of its academic Founders in the field of splicing factor kinase inhibition. The company is developing novel small molecules to modulate aberrant mRNA splicing and bring forward new medicines for the treatment of chronic pain and cancer.
- **14:15 - 14:30** **NanoSyrinx**, a discovery stage spin-out from the University of Warwick, developing a completely novel intracellular biologics delivery platform.
- **14:30 - 14:45** **Renovos Biologics**, a regenerative medicine company, is pioneering a nanoclay gel technology platform, Renovite<sup>®</sup>, for medical applications to address the unmet need for long term tissue regeneration, offering safer, more economic clinical solutions for health systems, and better outcomes for patients.
- **14:45 - 15:00** **Ability Pharmaceuticals**, is a biopharmaceutical company developing new first-in-class candidates to treat cancer. We are focused on autophagy as a new therapeutic strategy to induce cancer cell death. Based on this novel mechanism of action, we are generating a portfolio of new drugs targeting oncological unmet needs.
- **15:00 - 15:15** **Leadartis**, a biopharmaceutical company engaged in the development of proprietary therapeutic antibodies named Trimerbodies with higher multivalence and multispecificity than the immunoglobulins, which are currently most prevalent on the market.
- **15:15 - 15:30** **Myxobiotics**, developing the cystobactamid broad-spectrum anti-bacterial for treatment of cUTI and possibly HAP/VAP.

---

## 15:30 Panel Discussion: Building your Board - Structure, Diversity, Success

Our panel of internationally experienced Board profiles from the industry discussed the importance of an agile, forward-looking, tenacious and diverse Board for success in the healthcare sector. Amongst them, our panel have experienced what an impactful Board looks like and the momentum it can give any growth stage life science business for success.

*Chaired by: Maureen Coleman, Chairman, PiR International*

### Panellists:

- Eva-Lotta Allan, **Non-Executive Director and Chair**
  - Patrick Vink, **Non-Executive Chairman and Board Member**
  - Melanie Lee, **LifeArc**
  - Edwin Moses, **Independent Director**
-

### 16:15 Panel Discussion: If I knew then what I know now

**Mike Ward** Chaired a panel of industry executives who reflected on previous experiences and discussed key learnings from their careers.

*Chaired by: Mike Ward, Decision Resources Group, part of Clarivate*

#### **Panellists:**

- Catherine Moukheibir, **Non-Executive Director**
  - Roel Bulthuis, **INKEF Capital**
  - Renee Aguiar-Lucander, **Calliditas Therapeutics**
  - Steven Powell, **eTheRNA immunotherapies**
- 

### 17:15 Conclusions

Reflections on the days themes and topics by:

- Hakan Goker, **M Ventures**
  - Mary Clark, **Optimum Strategic Communications**
- 

Themed Networking rooms were provided throughout the day.

Our supported charity was Brain Tumour Research.

---

## 2021 Registered Delegates

### **Investors (82)**

3B Future Health Fund (formerly Helsinn Investment Fund), 4BIO Capital, Advent Life Sciences, Albion Technology & General VCT, Alpha Blue Ocean, Alpha Bronze Life Sciences Opportunity Fund, Apollo Ventures, Aratus Capital, Arix Bioscience, Arvic, Axilium Holding, Axon Capital Partners, BioLucidity Advisors, Bioscience Managers, Biotechnology Business Institute, Bond Asian Ventures, Cascara Ventures, Catapult Ventures, China Life Franklin Asset Management, Curam Capital Management, DeBere Capital Partners, Deep Science Ventures, Draper Esprit, Eir Ventures, Emerson Collective, ESM Biotech, Esperante, European Investment Bank, GIMV, GL Capital, GreenSky Capital, Hermes Partners Intl, i2020 Accelerator, Ignite Capital Partners, Inkef Capital, Innovate UK, Inveready Asset Management, IP Group, IPF Partners, Julz Co, Kreos Capital, Kurma Partners, Limerston Capital Partners, Longacre Funding Partners, Luminous Ventures, Lundbeckfonden Ventures, M Ventures, Mercia Asset Management, Momentum Biotech, MVM Partners, National Institute for Health Research, NeoMed, New Grounds Venture Capital, Newables and Syndicate Room, Norgine Ventures, Novalis Biotech Acceleration, Novo Holdings, NRW.BANK, o2h Ventures, Optum Ventures, Oxford Technology 3 VCT, Panakes Partners, Pontifax, Qestra, RBV Capital, R-Pharm, Rosetta Capital, Ruffena Capital, Seroba Life Sciences, Seventure Partners, SHS, SR One, SV

Health Investors, Swelife International, Syncona, Trilantic Europe, UCB Ventures, UK Innovation & Science Seed Fund, V-Bio Ventures, Vickers Venture Partners, Xeraya Capital, and XOventure.

## **Attending companies (95)**

Ability Pharmaceuticals, Achilles Therapeutics, Adare Pharma Solutions, Ahead Therapeutics, Antev, Aortyx, Artios Pharma, AstraZeneca, Bionow, BioPartner UK, Brain Tumour Research, C4X Discovery, Calliditas Therapeutics, Cell and Gene Therapy Catapult, CytoSeek, Danish Embassy in the UK, Decision Resources Group - part of Clarivate, Eli Lilly, Emenda Therapeutics, Endpoints News, eTheRNA immunotherapies, Ezenze, Formo, Gate2Brain, Gebro Pharma, GSK, ICEX-Invest in Spain, In Vivo - Pharma Intelligence, Indi Molecular, Informa Business Intelligence, Informa Pharma Intelligence, Invest in Denmark/Ministry of Foreign Affairs, Iomed, Isogenica, Isquaemia Biotech, Lanthio Health, Leadartis, LifeArc, Lifescience Industry News, LINK Medical, LSX, Lytix Biopharma, Macrophage Pharma, Marsi Bionics, MedCity, Medicon Valley Alliance, MediWales, Meeting Mojo, Merck, Midatech Pharma, Mosa Meat, Moxie Works, Mushlabs, Myxobiotics, NanoSyrinx, Negma Group, NxFoods, OBN, One Nucleus, Optimum Strategic Communications, Oxford Medical Products, Parkinson's Concierge, Parkinsongs, Pebmond Associates, Pfizer, Pharmalicensing - a division of Cognis Group, pharmaphorum, PIR International, Pluripotent Stem Cell and Engineered Cell Hub, ProAxis, Rapid News Group / Med-Tech Innovation, Renovos Biologics, Santerus, Science Entrepreneur Club, Scrip Pharma intelligence, SNIPR BIOME, South East Health Technologies Alliance (SEHTA), Spirea, Statens Serum Institut (SSI), STipe Therapeutics, Supplant, SurePulse, Sygnature Discovery, The Francis Crick Institute, The FreeMind Group, The Journal of mHealth, UK BioIndustry Association (BIA), Vaccibody, Vaximm, Versameb, WuXi AppTec, and Zerion Pharma.